All the news

People with HIV and HCV co-infection, with liver cirrhosis, who achieve sustained virological response (SVR) and experience an improvement in liver fibrosis are less likely to develop liver disease complications or die from ...

People with hepatitis C who were treated with AbbVie's Viekirax plus Exviera or '3D' regimen saw improvements in liver function biomarkers, had better quality of life and had increased survival compared to ...

Direct-acting antiviral regimens containing sofosbuvir (Sovaldi) and the drugs in Viekirax/Exviera were highly effective regardless of how soon hepatitis C viral load became undetectable after starting treatment, according to research presented at the recent ...

Rates of hepatitis C virus (HCV) reoccurrence after successful therapy differ markedly between risk groups, according to the results of a meta-analysis presented at the recent Conference on Retroviruses and Opportunistic Infections (CROI ...

Almost all patients with hepatitis C virus alone or HIV/HCV co-infection who achieved sustained virological response (SVR) to treatment with sofosbuvir (Sovaldi) plus ribavirin or sofosbuvir/ledipasvir (Harvoni) still had undetectable HCV RNA ...

People who achieve sustained virological response (SVR) when treated with interferon-based therapy for hepatitis C have a lower risk of death, are less likely to develop liver cancer and need fewer liver transplants ...